Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.57 |
| ▸ | CCND1 | P24385 | 4/20 | 0.57 |
| ▸ | DUT | P33316 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17683073 | 0.92 | CDK4 (0.54) | CDK4CCND1DUTHTR2AHTR2C | |
| SCHEMBL6030247 | 0.83 | HTR2A (0.54) | DUTHTR2AHTR2C | |
| SCHEMBL6260801 | 0.82 | DUT (0.52) | CDK4CCND1DUTHTR2AHTR2C | |
| SCHEMBL9094075 | 0.81 | DUT (0.51) | CDK4CCND1DUTHTR2AHTR2C | |
| SCHEMBL9093439 | 0.81 | DUT (0.51) | CDK4CCND1DUT | |
| SCHEMBL2263579 | 0.79 | DUT (0.52) | CDK4CCND1DUTHTR2CHTT | |
| SCHEMBL8252214 | 0.79 | DUT (0.49) | DUTHTT | |
| SCHEMBL6933502 | 0.78 | CDK4 (0.45) | CDK4CCND1HTR2AHTR2CMAPK1 | |
| SCHEMBL6030285 | 0.78 | DUT (0.51) | DUTHTR2C | |
| SCHEMBL6030279 | 0.78 | DUT (0.51) | DUTHTR2CMAPK1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109229-B2 | Methods and compounds for treating proliferative diseases | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1325011-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | LILLY CO ELI (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | ENGLER THOMAS ALBERT (US) | 2004-03-11 | — | — | US | disclosed |
| EP-1325011-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002028861-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | CDK4, CCNI, CCNA1 | CDK4 1/4885CCND1 32/4885DUT 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.